BSE Live
Apr 08, 09:17Prev. Close
339.70
Open Price
345.05
Bid Price (Qty.)
344.95 (16)
Offer Price (Qty.)
346.90 (29)
NSE Live
Apr 08, 09:17Prev. Close
339.20
Open Price
345.00
Bid Price (Qty.)
345.50 (31)
Offer Price (Qty.)
347.00 (63)
| Cash Flow of FDC (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 325.46 | 240.27 | 233.91 | 255.67 | 219.67 | |
| Net CashFlow From Operating Activities | 239.04 | 103.79 | 147.76 | 153.09 | 171.05 | |
| Net Cash Used In Investing Activities | -84.80 | -109.30 | 20.15 | -143.55 | -72.72 | |
| Net Cash Used From Financing Activities | -142.00 | -0.07 | -169.43 | 0.35 | -96.56 | |
| Foreign Exchange Gains / Losses | -0.08 | 0.00 | -0.19 | 0.02 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | |
| Net Inc/Dec In Cash And Cash Equivalents | 12.16 | -5.58 | -1.71 | 9.92 | 1.88 | |
| Cash And Cash Equivalents Begin of Year | 14.36 | 19.94 | 21.66 | 11.74 | 11.28 | |
| Cash And Cash Equivalents End Of Year | 26.52 | 14.36 | 19.94 | 21.66 | 13.16 |
10.02.2026
FDC Consolidated December 2025 Net Sales at Rs 464.71 crore, up 0.13% Y-o-Y
09.02.2026
FDC Standalone December 2025 Net Sales at Rs 457.94 crore, down 0.2% Y-o-Y
11.11.2025
FDC Standalone September 2025 Net Sales at Rs 461.74 crore, down 8.58% Y-o-Y
07.11.2025
FDC Consolidated September 2025 Net Sales at Rs 473.03 crore, down 7.94% Y-o-Y
10.02.2026
FDC Consolidated December 2025 Net Sales at Rs 464.71 crore, up 0.13% Y-o-Y
09.02.2026
FDC Standalone December 2025 Net Sales at Rs 457.94 crore, down 0.2% Y-o-Y
11.11.2025
FDC Standalone September 2025 Net Sales at Rs 461.74 crore, down 8.58% Y-o-Y
07.11.2025
FDC Consolidated September 2025 Net Sales at Rs 473.03 crore, down 7.94% Y-o-Y
08.04.2026
08.04.2026
07.04.2026
Kiran Mazumdar‑Shaw calls for new IPO rules to unlock India’s innovation potential in life sciences
07.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth